[{"name":"page-hero","instance":1,"visibility":["lg","md","sm"],"config":{"hero":{"enabled":true,"text":{"title":"Drug FAQ","desc":"Get the facts on the some of the latest prescription drugs approved for eczema."},"image":{"alt":"","desktop":{"src":"https://nationaleczema.org/wp-content/uploads/2022/02/shutterstock_740979067-1-1370x470.jpg","src2x":"https://nationaleczema.org/wp-content/uploads/2022/02/shutterstock_740979067-1.jpg","alignment":"center","width":1370,"height":470},"tabletLarge":{"src":false,"src2x":false,"alignment":"center","width":960,"height":470},"tabletSmall":{"src":false,"src2x":false,"alignment":"center","width":720,"height":470},"mobile":{"src":"https://nationaleczema.org/wp-content/uploads/2022/02/shutterstock_740979067-1-375x410.jpg","src2x":"https://nationaleczema.org/wp-content/uploads/2022/02/shutterstock_740979067-1-750x820.jpg","alignment":"center","width":375,"height":410}}},"feed":{"title":"","subtitle":"","link_text":"View All","link_url":"","items":[]}}},{"name":"wysiwyg","instance":1,"visibility":["lg","md","sm"],"config":{"wysiwyg":"\u003Cp\u003ENew medications are being approved every year by the FDA to treat and manage various types of eczema. Get the details on the latest eczema prescription drugs to see what might work for you. Learn how each drug works, who can take it, effectiveness, side effects and more.\u003C/p\u003E","maxWidth":"","content":"\u003Cp\u003ENew medications are being approved every year by the FDA to treat and manage various types of eczema. Get the details on the latest eczema prescription drugs to see what might work for you. Learn how each drug works, who can take it, effectiveness, side effects and more.\u003C/p\u003E\n","scripts":[]}},{"name":"page-hero","instance":2,"visibility":["lg","md","sm"],"config":{"hero":{"enabled":false},"feed":{"title":"Injectables","subtitle":"These are medicines that are given by injection or needle.","link_text":"View All","link_url":"","items":[{"image":"https://nationaleczema.org/wp-content/uploads/2022/01/Adbry-package-320x190.jpeg","image2x":"https://nationaleczema.org/wp-content/uploads/2022/01/Adbry-package-640x380.jpeg","alt":"adbry","title":"Adbry (tralokinumab-ldrm) FAQ","desc":"Adbry (tralokinumab-ldrm) is a biologic drug approved by the FDA for people ages 12 and older with moderate to severe atopic dermatitis.","url":"https://nationaleczema.org/tralokinumab-faq/"},{"image":"https://nationaleczema.org/wp-content/uploads/2021/04/Website_NewTreatments_FAQ_Dupixent-320x190.png","image2x":"https://nationaleczema.org/wp-content/uploads/2021/04/Website_NewTreatments_FAQ_Dupixent.png","alt":"","title":"Dupixent (Dupilumab) FAQ","desc":"Dupixent (dupilumab) is a biologic drug approved by the FDA for adults and children (6 months and up) with moderate to severe atopic dermatitis. ","url":"https://nationaleczema.org/dupilumab-faq/"},{"image":"https://nationaleczema.org/wp-content/uploads/2025/05/ebglyss.png","image2x":"https://nationaleczema.org/wp-content/uploads/2025/05/ebglyss.png","alt":"","title":"Ebglyss (Lebrikizumab-lbkz) FAQ","desc":"Ebglyss (lebrikizumab-lbkz) is a biologic drug approved by the FDA for people ages 12 and older (who weigh at least 88 pounds) with moderate to severe atopic dermatitis (AD).","url":"https://nationaleczema.org/ebglyss-faq/"},{"image":"https://nationaleczema.org/wp-content/uploads/2025/05/nemluvio-300x190.png","image2x":"https://nationaleczema.org/wp-content/uploads/2025/05/nemluvio.png","alt":"nemluvio","title":"Nemluvio (Nemolizumab-ilto) FAQ","desc":"Nemluvio (nemolizumab-ilto) is a biologic drug approved by the FDA for people ages 12 and older with moderate to severe atopic dermatitis.","url":"https://nationaleczema.org/faq-galderma-nemluvio/"}]}}},{"name":"page-hero","instance":3,"visibility":["lg","md","sm"],"config":{"hero":{"enabled":false},"feed":{"title":"Topicals","subtitle":"These are creams, gels and lotions that are applied to the skin.","link_text":"View All","link_url":"","items":[{"image":"https://nationaleczema.org/wp-content/uploads/2021/04/Website_NewTreatments_FAQ_Eucrisa-320x190.png","image2x":"https://nationaleczema.org/wp-content/uploads/2021/04/Website_NewTreatments_FAQ_Eucrisa.png","alt":"","title":"Eucrisa (Crisaborole) FAQ","desc":"Eucrisa (crisaborole) is a topical phosphodiesterase 4 inhibitor (PDE4) drug approved by the FDA for mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. ","url":"https://nationaleczema.org/crisaborole-faq/"},{"image":"https://nationaleczema.org/wp-content/uploads/2021/09/Opzelura-Incyte-corp-320x190.jpeg","image2x":"https://nationaleczema.org/wp-content/uploads/2021/09/Opzelura-Incyte-corp-640x380.jpeg","alt":"","title":"Opzelura (Ruxolitinib) FAQ","desc":"Opzelura (ruxolitinib 1.5%) cream is a topical selective Janus kinase (JAK) inhibitor approved by the FDA for the short-term and non-continuous treatment of mild to moderate atopic dermatitis in patients 12 years of age and older.","url":"https://nationaleczema.org/ruxolitinib-faq/"},{"image":"https://nationaleczema.org/wp-content/uploads/2025/01/ht_240215_vtama_800x450-320x190.avif","image2x":"https://nationaleczema.org/wp-content/uploads/2025/01/ht_240215_vtama_800x450-640x380.avif","alt":"","title":"Vtama® (tapinarof) FAQ","desc":"Vtama (tapinarof) cream (1%) is an aryl hydrocarbon receptor (AHR) agonist approved by the FDA for the topical treatment of atopic dermatitis in adults and children 2 years of age and older.","url":"https://nationaleczema.org/faq-organon-vtama/"},{"image":"https://nationaleczema.org/wp-content/uploads/2025/05/zoryve.png","image2x":"https://nationaleczema.org/wp-content/uploads/2025/05/zoryve.png","alt":"","title":"Zoryve (roflumilast) FAQ","desc":"Zoryve (roflumilast) is a topical treatment approved by the FDA for seborrheic dermatitis and atopic dermatitis.","url":"https://nationaleczema.org/faq-zoryve-roflumilast-foam-0-3/"}]}}},{"name":"page-hero","instance":4,"visibility":["lg","md","sm"],"config":{"hero":{"enabled":false},"feed":{"title":"Orals","subtitle":"These are pills and liquids you take orally.","link_text":"View All","link_url":"","items":[{"image":"https://nationaleczema.org/wp-content/uploads/2022/02/cibinqo-320x190.png","image2x":"https://nationaleczema.org/wp-content/uploads/2022/02/cibinqo-439x380.png","alt":"","title":"Cibinqo (Abrocitinib) FAQ","desc":"Cibinqo (abrocitinib) is an oral JAK1 inhibitor approved by the FDA for adults and adolescents aged 12+ years with moderate to severe atopic dermatitis. ","url":"https://nationaleczema.org/faq-cibinqo-abrocitinib/"},{"image":"https://nationaleczema.org/wp-content/uploads/2022/02/rinvoq-image-320x190.png","image2x":"https://nationaleczema.org/wp-content/uploads/2022/02/rinvoq-image-640x380.png","alt":"","title":"Rinvoq (Upadacitinib) FAQ","desc":"Rinvoq (upadacitinib) is an oral JAK1 inhibitor approved by the FDA for adults and adolescents aged 12+ years with moderate to severe atopic dermatitis.","url":"https://nationaleczema.org/faq-upadacitinib/"}]}}}]
